Bitolterolum

Bitolterolum Uses, Dosage, Side Effects, Food Interaction and all others data.

Bitolterolum mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterolum was withdrawn from the market by Elan Pharmaceuticals in 2001.

Bitolterolum, an adrenergic bronchodilator, is a prodrug that widens constricted airways in the lungs by relaxing the smooth muscles that surround the bronchial passages. Bitolterolum probably does not affect the inflammation in the lung, such as in bronchitis. Bitolterolum is unique in that it is a prodrug because it must first be metabolized by the body before it becomes active.

Bitolterolum
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Bitolterolum
Availability	Discontinued
Generic	Bitolterol
Bitolterol Other Names	Bitolterol, Bitoltérol, Bitolterolum
Related Drugs	Dupixent, Xolair, ProAir Digihaler, albuterol, azithromycin, dexamethasone, methylprednisolone, Symbicort, Zithromax, Breo Ellipta
Type
Formula	C₂₈H₃₁NO₅
Weight	Average: 461.5494 Monoisotopic: 461.220223107
Groups	Withdrawn
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Used to dilate air passages in the lungs that have become narrowed as a result of disease or inflammation. It is used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

How Bitolterolum works

Bitolterolum is an adrenergic beta-2 agonist. Asthma results from a narrowing of the bronchial tubes. This narrowing is caused by muscle spasm and inflammation within the bronchial tubes. Agonism of the beta-2 adrenergic receptors by bitolterol leads to a relaxation of the smooth muscles surrounding these airway tubes which then increases the diameter and ease of air flow through the tubes.

Bitolterolum Hypertension interaction

[Moderate] Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).

Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.

However, beta-2-selectivity is not absolute and can be lost with larger doses.

High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.

Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and

The recommended dosages should not be exceeded.